For acute patients hospitalized for a clinical disease (e.g.: heart failure), indicating rivaroxaban for 6.5 weeks after discharge did not significantly reduce the risk of symptomatic venous thromboembolism. Efficacy primary end point rate was low, with 0.83% in patients treated with rivaroxaban vs 1.1% of patients receiving placebo. This work presented at ESC and…